logo
ResultsCX Earns Great Place To Work® Certification™ in Seven Countries, Including First Time Recognition in India and the UK

ResultsCX Earns Great Place To Work® Certification™ in Seven Countries, Including First Time Recognition in India and the UK

Business Wire24-06-2025
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- ResultsCX, a provider of Customer Experience Management (CXM) services to leading global companies including Fortune 100 and FTSE 250 firms, today announced it was certified in seven countries by Great Place To Work®, the global authority on workplace culture, employee experience, and leadership. This year's award marks the fourth consecutive year ResultsCX's United States location has earned Great Place To Work® Certification ™, with the company's operations in Honduras, Mexico, Philippines and Bulgaria receiving this distinction for multiple years, and its India and UK operations achieving certification for the first time.
'The past two years have been a period of rapid expansion for ResultsCX. What truly sets this growth apart is our ability to integrate not just at the technological and operational levels, but at a much deeper cultural level,' said ResultsCX Chief Executive Officer Rajesh Subramanian. 'Since 2022, we have completed three strategic acquisitions and launched new customer operations in India. Throughout this journey, our teams have continued to foster an inclusive culture while prioritizing employee wellbeing across a diverse and evolving workforce. The consecutive certifications by Great Place To Work® are a testament to this commitment.'
As a purpose-driven employer, ResultsCX is committed to creating positive workplace environments across its global operations, ensuring that all employees feel included and seen. The company has consistently demonstrated its commitment to an inclusive and engaging culture through initiatives focused on gender equity, professional development, and environmental, social, and governance (ESG) impact. These efforts are reflected in the latest Great Place To Work® survey, where the company received positive feedback.
'Our focus is squarely on the wellbeing of our employees," said ResultsCX Chief Human Resources Officer Mark Cunningham. 'By creating the right environment and fostering a supportive culture, we achieve exceptional results for our employees and our customers. This recognition reflects the collective commitment of our entire team to making this a truly exceptional place to work.'
According to Great Place To Work® research, job seekers are 4.5 times more likely to find a great manager at a Certified great workplace. Additionally, employees at Certified workplaces are 93% more likely to look forward to coming to work, and are twice as likely to be paid fairly, earn a fair share of the company's profits, and have a fair chance at promotion.
'Great Place To Work® Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,' says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work®. 'By successfully earning this recognition, it is evident that ResultsCX stands out as one of the top companies in the world to work for, providing a great workplace environment for its employees.'
About Great Place To Work ® Certification™
Great Place To Work® Certification™ is the most definitive 'employer-of-choice' recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work® Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work® Certified.
About Great Place To Work ®
As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a Great Place To Work® for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work® Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at greatplacetowork.com.
About ResultsCX
ResultsCX is a leading provider of transformational Customer Experience Management (CXM) solutions to 130+ global brands, including Fortune 100 and FTSE 250 companies. For 30+ years, we have been driving superior customer and business outcomes for brands across Healthcare, Media, Telecom, Fast Growth technology, Retail, Banking and Financial Services, and other industries globally.
Our award-winning approach helps brands prioritize investments and build digitally influenced customer journeys, creating high-value impact across three areas: Revenue Acceleration, Cost Optimization, and Enhanced Experience. Supported by 24,000+ colleagues and 23 engagement hubs worldwide, our innovative solutions and services solve persistent customer experience challenges, making life easier for millions of consumers. For more information about ResultsCX and its award-winning customer experience solutions, please visit www.resultscx.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cybin Announces Results of Annual Meeting of Shareholders
Cybin Announces Results of Annual Meeting of Shareholders

Business Wire

time2 minutes ago

  • Business Wire

Cybin Announces Results of Annual Meeting of Shareholders

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the ' Meeting '). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: 1. Appointment of Auditor Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below: 2. Number of Directors The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below: 3. Election of Directors Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below: George Tziras did not stand for re-election as a director. The Company thanks Mr. Tziras for his past service. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.

Capvidia brings MBD for Suppliers with browser-based 3D human-viewable models linked to QIF/STEP
Capvidia brings MBD for Suppliers with browser-based 3D human-viewable models linked to QIF/STEP

Business Wire

time2 minutes ago

  • Business Wire

Capvidia brings MBD for Suppliers with browser-based 3D human-viewable models linked to QIF/STEP

CHICAGO--(BUSINESS WIRE)-- Capvidia, a global leader in Model-Based Definition (MBD) and Model-Based Enterprise (MBE) software, announced a major milestone for MBDVidia: 3D human-viewable HTML models synchronized with QIF and STEP AP242. The result is OEM MBD that suppliers can use anywhere with no CAD required. How it works: MBDVidia publishes standards-based QIF/STEP from native CAD (Creo, CATIA, SOLIDWORKS, Autodesk, etc.) and now generates a linked HTML viewable (and PDF). Any browser can open the interactive 3D model and PMI, giving procurement, manufacturing, quality, and the shop floor a shared, authoritative view in a user-friendly way. Why it matters for Suppliers: No CAD seats: Open interactive 3D + PMI in any modern browser. Faster RFQs: See features, GD&T, and tolerances in 3D to quote accurately. Fewer errors: Viewable is linked to QIF/STEP and native CAD—preserves intent. Bill of Characteristics click-through: Jump from each characteristic to the exact PMI on the model. Shop-floor friendly: Zoom, section, filter PMI; run on tablets or kiosks. Quality ready: Linked QIF speeds FAI/PPAP and audit-ready traceability. Clear changes: Model-to-characteristic traceability improves ECO handling. Start 2D → scale 3D: Use HTML as a low-friction on-ramp from PDFs. 'Capvidia is about simplifying collaboration between OEMs and suppliers,' said Tomasz Luniewski, CEO of Capvidia. 'By pairing standards-based QIF/STEP with an interactive browser view, we make MBD universally accessible so quoting, programming, and quality teams can move faster with fewer mistakes.' Learn more: MBDVidia at Get MBD ready: Request a demo at About Capvidia Capvidia is the global authority on MBD/MBE. We make the 3D model the single source of truth, auto-generating PMI and characteristics to eliminate manual ballooning and automate workflows from design through quality. Built on open standards (QIF, STEP AP242) and native CAD, our software delivers true interoperability across CAD, CAM, CMM, and PLM—without loss of intent. The result is a complete, auditable, traceable digital thread linking every requirement to real-world results across OEMs and suppliers. Trusted by leading aerospace, defense, medical-device, and industrial manufacturers, Capvidia helps teams move faster, prove conformance, and collaborate with confidence.

Everspin to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit
Everspin to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit

Yahoo

time11 minutes ago

  • Yahoo

Everspin to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit

CHANDLER, Ariz., August 18, 2025--(BUSINESS WIRE)--Everspin Technologies, Inc. (NASDAQ: MRAM), the world's leading developer and manufacturer of Magnetoresistive Random Access Memory (MRAM) persistent memory solutions, today announced that it will participate in a fireside chat at the Lytham Partners 2025 Consumer & Technology Investor Summit, taking place virtually on Tuesday, August 19, 2025. The webcast will take place at 11:30 a.m. ET on Tuesday, August 19, 2025 and can be accessed by visiting the conference home page at or directly at An archive of the presentation will also be available through the same links for one year About Everspin Technologies Everspin Technologies, Inc. is the world's leading provider of Magnetoresistive RAM (MRAM). Everspin MRAM delivers the industry's most robust, highest performance non-volatile memory for Industrial IoT, Data Center, and other mission-critical applications where data persistence is paramount. Headquartered in Chandler, Arizona, Everspin provides commercially available MRAM solutions to a large and diverse customer base. For more information, visit NASDAQ: MRAM. View source version on Contacts Investor RelationsThe Blueshirt GroupMonica Gould212-871-3927ir@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store